A pharmaceutical composition comprising as an active ingredient a DPP IV inhibitor compound with a fkee or primary amino group, which is 1-[(4-methyl-quinazolin-2- y 1)methy 1] -3 -methyl-7-(2-butyn- 1 - yl)-8 -(3 -(R)-amino-piperidin- 1 - y1)-xanthine, or a salt thereof, a first diluent, a second diluent, a binder, a disintegrant and a lubricant wherein the pharmaceutical composition comprises 0.5-7 wt.% active ingredient wherein the DPP IV inhibitor is contained in an amount of 0.5 mg to 10 mg and wherein the diluents are selected fiom cellulose powder, dibasic calciumphosphate anhydrous, dibasic calciumphosphate dihydrate, erythntol, low substituted hydroxypropyl cellulose, mannitol, pregelatinized starch, and xylitol with the proviso that a pharmaceutical composition comprising: a DPP IV inhibitor compound, which is l-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2- butyn- 1 - yl)-8-(3 -(R)-amino-piperidin- 1 - y - a n or a salt thereof, a first diluent which is mannitol, a second diluent which is pregelatinized starch, a binder which is copovidone, a disintegrant which is corn starch, and a lubricant which is magnesium stearate, is excluded fiom the pharmaceutical composition.
